Evidence map›Paper›PMID 33123612›Full record

ArticleOpen forum infectious diseases2020

Association of Hepatitis B Core-Related Antigen and Antihepatitis B Core Antibody With Liver Fibrosis Evolution in Human Immunodeficiency Virus-Hepatitis B Virus Coinfected Patients During Treatment With Tenofovir.

Romuald Cruchet, Lorenza N C Dezanet, Sarah Maylin, Audrey Gabassi, Hayette Rougier, Patrick Miailhes, Caroline Lascoux-Combe, Julie Chas, Pierre-Marie Girard, Constance Delaugerre and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Romuald CruchetSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.ORCID 0000-0003-0459-1736
Lorenza N C DezanetSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.
Sarah MaylinAPHP, Hôpital Saint-Louis, Laboratoire de Virologie, Paris, France.
Audrey GabassiAPHP, Hôpital Saint-Louis, Laboratoire de Virologie, Paris, France.
Hayette RougierIMEA, Institut de Médecine et d'Epidémiologie Appliquée, Paris, France.
Patrick MiailhesHôpital de la Croix-Rousse, Hospices Civils de Lyon, Service des Maladies Infectieuses et Tropicales, Lyon, France.
Caroline Lascoux-CombeAPHP, Hôpital Saint-Louis, Service de Maladies Infectieuses, Paris, France.
Julie ChasAPHP, Hôpital Tenon, Service de Maladies Infectieuses, Paris, France.
Pierre-Marie GirardAPHP, Hôpital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris, France.
Constance DelaugerreAPHP, Hôpital Saint-Louis, Laboratoire de Virologie, Paris, France.
Karine LacombeSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.
Anders BoydSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.
Inserm · FRAssistance Publique – Hôpitaux de Paris · FRSorbonne Université · FRUniversity of London Institute in Paris · FRHôpital de la Croix-Rousse · FRInstitut de Médecine et d'Epidémiologie Africaines · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundQuantitative hepatitis B core-related antigen (qHBcrAg) or antihepatitis B core antibody (qAnti-HBc) could be useful in monitoring liver fibrosis evolution during chronic hepatitis B virus (HBV) infection, yet it has not been assessed in human immunodeficiency virus (HIV)-HBV-coinfected patients undergoing treatment with tenofovir (TDF).

methodsOne hundred fifty-four HIV-HBV-infected patients initiating a TDF-containing antiretroviral regimen were prospectively followed. The qHBcrAg and qAnti-HBc and liver fibrosis assessment were collected every 6-12 months during TDF. Hazard ratios (HRs) assessing the association between qHBcrAg/qAnti-HBc and transitions from none/mild/significant fibrosis to advanced fibrosis/cirrhosis (progression) and from advanced fibrosis/cirrhosis to none/mild/significant fibrosis (regression) were estimated using a time-homogeneous Markov model.

resultsAt baseline, advanced liver fibrosis/cirrhosis was observed in 40 (26%) patients. During a median follow-up of 48 months (interquartile range, 31-90), 38 transitions of progression (IR = 7/100 person-years) and 34 transitions of regression (IR = 6/100 person-years) were observed. Baseline levels of qHBcrAg and qAnti-HBc were not associated with liver fibrosis progression (adjusted-HR per log

conclusionsBaseline qHBcrAg and qAnti-HBc levels are not associated with liver fibrosis evolution in TDF-treated HIV-HBV coinfected patients. The link between changes in qAnti-HBc levels during follow-up and liver fibrosis regression merits further study.

Indexed as

antihepatitis B core antibodycirrhosishepatitis B core-related antigenhuman immunodeficiency virusliver fibrosis

Identifiers

PMID33123612
PMCPMC7580158
OpenAlexW3033550419

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.